Boehringer Ingelheim and OSE Immunotherapeutics SA (OSE), a clinical stage biotech company, announced that Boehringer will be progressing their first-in-class SIRPα immuno-oncology program into...
I-Mab, a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, announced...
Thermo Fisher Scientific, the global leader in serving science, and Arsenal Biosciences, Inc. , a cell therapy clinical development company, to develop novel chimeric...
Deka Biosciences, a biotech company focused on developing novel cytokine therapies to treat cancer and inflammatory diseases, announced that the U.S. Food and Drug...
Hemispherian AS, a Norwegian preclinical pharmaceutical company focused on small molecule cancer therapeutics targeting the DNA damage response, is delighted to announce the closure...
